David Moatazadi

CHIEF EXECUTIVE, PRESIDENT, EVOLUS INC.

Injectable neurotoxin, forehead wrinkles … FDA action pending, Feb 2019 after May 2018 decline, Aug. resubmitted … Canada OK, 2018 … Feb 2018 IPO, $12, raised $60M at $280M valuation … secondary offering: 3M shares at $20, July … Oct 2018: $18, $466M market cap … Moatazedi led Allergan’s aesthetics, buys: $2.9B, regenerative tissue maker LifeCell; $2.5B, fat cooling firm Zeltiq … added ex-AGN execs … lives NB, wife, 3 kids